\u3ci\u3en\u3c/i\u3e-Type Charge Transport in Heavily \u3ci\u3ep\u3c/i\u3e-Doped Polymers

It is commonly assumed that charge-carrier transport in doped π-conjugated polymers is dominated by one type of charge carrier, either holes or electrons, as determined by the chemistry of the dopant. Here, through Seebeck coefficient and Hall effect measurements, we show that mobile electrons contribute substantially to charge-carrier transport in π-conjugated polymers that are heavily p-doped with strong electron acceptors. Specifically, the Seebeck coefficient of several p-doped polymers changes sign from positive to negative as the concentration of the oxidizing agents FeCl3 or NOBF4 increase, and Hall effect measurements for the same p-doped polymers reveal that electrons become the dominant delocalized charge carriers. Ultraviolet and inverse photoelectron spectroscopy measurements show that doping with oxidizing agents results in elimination of the transport gap at high doping concentrations. This approach of heavy p-type doping is demonstrated to provide a promising route to high-performance n-type organic thermoelectric materials

Detection of Sclerotic Spine Metastases via Random Aggregation of Deep Convolutional Neural Network Classifications

Automated detection of sclerotic metastases (bone lesions) in Computed Tomography (CT) images has potential to be an important tool in clinical practice and research. State-of-the-art methods show performance of 79 % sensitivity or truepositive (TP) rate, at 10 false-positives (FP) per volume. We design a two-tiered coarse-to-fine cascade framework to first operate a highly sensitive candidate generation system at a maximum sensitivity of ∼92% but with high FP level (∼50 per patient). Regions of interest (ROI) for lesion candidates are generated in this step and function as input for the second tier. In the second tier we generate N 2D views, via scale, random translations, and rotations with respect to each ROI centroid coordinates. These random views are used to train a deep Convolutional Neural Network (CNN) classifier. In testing, the CNN is employed to assign individual probabilities for a new set of N random views that are averaged at each ROI to compute a final per-candidate classification probability. This second tier behaves as a highly selective process to reject difficult false positives while preserving high sensitivities. We validate the approach on CT images of 59 patients (49 with sclerotic metastases and 10 normal controls). The proposed method reduces the number of FP/vol.from 4 to 1.2, 7 to 3, and 12 to 9.5 when comparing a sensitivity rates of 60, 70, and 80% respectively in testing. The Area-Under-the-Curve (AUC) is 0.834. The results show marked improvement upon previous work

Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center

Background: BBI608 is an investigational reactive oxygen species generator that affects several molecular pathways. We investigated BBI608 combined with immune checkpoint inhibitors in patients with advanced cancers. Methods: BBI608 (orally twice daily) was combined with ipilimumab (3 mg/kg IV every 3 weeks); pembrolizumab (2 mg/kg IV every 3 weeks); or nivolumab (3 mg/kg IV every 4 weeks). We assessed the safety, antitumor activity and the pharmacokinetic profile of BBI combined with immunotherapy. Results: From 1/2017 to 3/2017, 12 patients were treated (median age, 54 years; range, 31–78; 6 men). Treatment was overall well tolerated. No dose-limiting toxicity was observed. The most common adverse events were diarrhea (5 patients: grade (G)1–2, n = 3; G3, n = 2) and nausea (4 patients, all G1). Prolonged disease stabilization was noted in five patients treated with BBI608/nivolumab lasting for 12.1, 10.1, 8.0, 7.7 and 7.4 months. The median progression-free survival was 2.73 months. The median overall survival was 7.56 months. Four patients had prolonged overall survival (53.0, 48.7, 51.9 and 48.2 months). Conclusions: Checkpoint inhibitors combined with BBI608 were well tolerated. Several patients had prolonged disease stabilization and overall survival. Prospective studies to elucidate the mechanisms of response and resistance to BBI608 are warranted